<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364335</url>
  </required_header>
  <id_info>
    <org_study_id>NS-WM-01</org_study_id>
    <nct_id>NCT03364335</nct_id>
  </id_info>
  <brief_title>The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of Effects of Two Fixed-dose Leucine-sildenafil Combinations (NS-0300) or Two Fixed-dose Leucine-sildenafil-metformin Combinations (NS-0200) Versus Placebo on Body Weight in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuSirt Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuSirt Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and
      sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to
      placebo. The primary objective of this study is to evaluate the percentage change in body
      weight in subjects from Baseline/Visit 2 (Day 1) to Study Termination/Visit 8 (Day 168/Week
      24).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, 24-week, placebo-controlled, double-blind study to evaluate the effects
      of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of
      leucine, sildenafil and metformin compared to placebo. Subjects meeting all the inclusion
      criteria and no exclusion criteria will be randomized to one of five study arms.

      The primary objective of this study is to evaluate the percentage change in body weight in
      subjects from Baseline/Visit 2 (Day 1) to Study Termination/Visit 8 (Day 168/Week 24)
      receiving two fixed-dose combinations of leucine and sildenafil or two fixed-dose
      combinations of leucine, sildenafil and metformin compared to placebo. Secondary objectives
      will also assess changes in absolute body weight, percentage of patients with ≥5% body weight
      loss, change in waist circumference, change in HbA1c, change in fasting glucose, change in
      blood lipids such as cholesterol, LDL, HDL, triglycerides, change in blood pressure and
      changes in in C-reactive protein. In addition this study will evaluate the safety and
      tolerability of NS-0200 and NS-0300.

      Patients will have one screening visits which will determine their eligibility based on lab
      tests. Once qualified, patients will be randomly assigned to either one of the treatment
      groups or the placebo control group and monitored for a total of 24 weeks. Patients will
      return to the clinic each month for lab tests, and routine examinations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Actual">August 17, 2018</completion_date>
  <primary_completion_date type="Actual">August 6, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This is a double blind, placebo controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Body Weight Change</measure>
    <time_frame>Baseline to Day 168</time_frame>
    <description>The percentage body weight change from baseline to Day 168 was evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Absolute Body Weight</measure>
    <time_frame>Baseline to Day 168</time_frame>
    <description>The change in absolute body weight from baseline to day 168 was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Patients With ≥5% Body Weight Loss</measure>
    <time_frame>Baseline to Day 168</time_frame>
    <description>The number of patients with ≥5% body weight loss in each group was assessed from baseline to day 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>Baseline to Day 168</time_frame>
    <description>The change in waist circumference by using a tape measure across the mid-section was evaluated in subjects from baseline to day 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol</measure>
    <time_frame>Baseline to Day 168</time_frame>
    <description>Changes in total cholesterol was examined by standard blood chemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL Cholesterol</measure>
    <time_frame>Baseline, Day 168</time_frame>
    <description>Changes were measured in HDL cholesterol from Baseline to day 168 by standard blood chemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol</measure>
    <time_frame>Baseline, 168 days</time_frame>
    <description>Changes in LDL Cholesterol was measured by standard blood chemistry from baseline to day 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>Baseline, Day 168</time_frame>
    <description>The change in triglycerides was evaluated by standard blood chemistry in subjects from Baseline to Day 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Glucose</measure>
    <time_frame>Baseline to Day 168</time_frame>
    <description>Change in plasma glucose was examined through standard fasting blood chemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Day 168</time_frame>
    <description>Change in Hemoglobin A1c was assessed in the subjects from baseline to day 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>Baseline to Day 168</time_frame>
    <description>Diastolic blood pressure was measured by standard blood pressure monitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>Baseline, Day 168</time_frame>
    <description>Change in Systolic blood pressure was assessed in patients from baseline to Day 168</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Markers</measure>
    <time_frame>Baseline to Day 168</time_frame>
    <description>hs-C-Reactive Protein (CRP) levels was examined by standard blood chemistry.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each dose of placebo will consist of three tablets, identical in appearance to those used in the two active treatment arms, containing 93.5% Microcrystalline cellulose PH 102, 5.0% Crospovidone XL 10, 1.0% Silica gel (Syloid 244), 0.5% Magnesium stearate I MF3V for the leucine matched placebo and 99.5% Avicel PH200 , 0.5% magnesium stearate (w/w) and Opadry II White coating 3% weight gain for the sildenafil matched placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leu Sil 1.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leu Sil 4.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leu Met Sil 1.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leu Met Sil 4.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leu Sil 1.0mg</intervention_name>
    <description>Leu 1100 mg + 1mg Sil BID</description>
    <arm_group_label>Leu Met Sil 1.0mg</arm_group_label>
    <arm_group_label>Leu Met Sil 4.0mg</arm_group_label>
    <arm_group_label>Leu Sil 1.0mg</arm_group_label>
    <arm_group_label>Leu Sil 4.0mg</arm_group_label>
    <other_name>NS-0300-1.0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leu Sil 4.0mg</intervention_name>
    <description>Leu 1100 mg + 4mg Sil BID</description>
    <arm_group_label>Leu Met Sil 1.0mg</arm_group_label>
    <arm_group_label>Leu Sil 1.0mg</arm_group_label>
    <other_name>NS-0300-4.0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leu Met Sil 1.0mg</intervention_name>
    <description>Leu 1100 mg + Met 500mg + 1mg Sil BID</description>
    <arm_group_label>Leu Met Sil 4.0mg</arm_group_label>
    <arm_group_label>Leu Sil 4.0mg</arm_group_label>
    <other_name>NS-0200-1.0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leu Met Sil 4.0mg</intervention_name>
    <description>Leu 1100 mg + Met 500mg + 4mg Sil BID</description>
    <arm_group_label>Leu Met Sil 1.0mg</arm_group_label>
    <arm_group_label>Leu Met Sil 4.0mg</arm_group_label>
    <other_name>NS-0200-4.0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 and ≤65 at study entry.

          2. Is male, or female and, if female, meets all of the following criteria:

               1. Not breastfeeding

               2. Post-menopausal or negative serum pregnancy test result (human chorionic
                  gonadotropin, beta subunit [β-hCG]) at Screening/Visit 1 (Day-7/Week-1) (not
                  required for hysterectomized females)

               3. If of childbearing potential (including peri-menopausal women who have had a
                  menstrual period within one year) must practice and be willing to continue to
                  practice appropriate birth control (defined as a method which results in a low
                  failure rate, i.e., less than 1% per year, when used consistently and correctly,
                  such as double barrier methods [male condom with spermicide, with or without
                  cervical cap or diaphragm], implants, injectables, oral contraceptives [must have
                  been using for at least the last 3 months], some intrauterine contraceptive
                  devices, tubal ligation, or in an established relationship with a vasectomized or
                  same sex partner) during the entire duration of the study

          3. Stable body weight (±5%) and health over the last 3 months.

          4. Has a BMI between 30 kg/m2 and 45 kg/m2

          5. Stable diet within the last three months

          6. Subjects on antidepressants, excluding those listed in the exclusion criteria, must
             have been on a stable dose regiment for at least 3 months prior to study enrollment
             and maintain stable dose during the study

          7. Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) either
             normal, not clinically significant or with abnormalities consistent with obesity

          8. Is able to read, understand, and sign the informed consent forms (ICF) and, when
             applicable, an authorization to use and disclose protected health information form
             (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA]
             legislation), communicate with the investigator, and understand and comply with
             protocol requirements.

        Exclusion Criteria:

          1. Diagnosis of diabetes or on a diabetes medication

          2. HbA1c ≥6.5% at Screening/Visit 1 (Day-7/Week-1)

          3. Severe renal impairment (eGFR &lt; 45 mg/mL/1.73 m2) and/or patients with acute or
             chronic metabolic acidosis. Acidosis is defined as &gt;25mmol/L computed without K.

             Normal is 8- 16, but acidosis is &gt;25

          4. Use of any of the following medications in the eight weeks prior to entering screening
             for study participation and during the study:

               1. Use of any anti-diabetes medication including metformin and any combination drug
                  that contains metformin

               2. Sildenafil

               3. Tadalafil

               4. Vardenafil

               5. OCT2/MATE inhibitors (e.g. cimetidine, quinidine, and pyrimethamine)

               6. Riociguat (guanylate cyclase stimulant)

               7. Alpha blockers

               8. Nitrates (e.g. oral nitrates, sublingual nitroglycerine and nitroglycerine
                  patches)

               9. Potent CYP3A4 inhibitors (e.g. clarithromycin, telithromycin, nefazodone,
                  itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir,
                  nelfinavir, ritonavir, saquinavir, tipranavir)

              10. All antihypertensive medications

              11. Medications associated with weight changes

                    -  Drugs approved for the treatment of obesity

                    -  Cypropheptadine or medroxyprogesterone

                    -  Atypical anti-psychotic drugs

                    -  Tricyclic antidepressants

                    -  Lithium, MAO's, glucocorticoids

                    -  SSRI's or SNRI's

                    -  Antiepileptic drugs

                    -  Systemic corticosteroids

                    -  Stimulants e.g. amphetamines

              12. Any dietary supplement that is labeled for weight management or maintenance of
                  healthy weight

          5. Diagnosis or evidence of eating disorders

          6. ≥ 5% weight change in the last 3 months

          7. Subjects who have had bariatric surgery

          8. An infection requiring antibiotic treatment within the last 30 days

          9. Any chronic inflammatory disease, e.g. inflammatory bowel disease rheumatoid
             arthritis, vasculitis, systemic lupus erythematosus

         10. Diseases interfering with metabolism (including metabolism of branched chain amino
             acids) and/or ingestive behavior (myxedema, Cushing's disease, diabetes,
             schizophrenia, major psychoses, maple syrup urine disease, unmanaged depression etc.)

         11. History of alcohol abuse (defined ≥ 21 drinks per week for males and &gt; 14 drinks per
             week for females), within the past 3 months or failure on urinary drug screen

         12. History of substance abuse (including alcohol abuse as defined above) in the past 12
             months or a positive screen for drugs (opioids without a prescription), including
             marijuana, of abuse or alcohol at screening.

         13. Has received any investigational drug within 3 months of Screening.

         14. Has donated blood within 3 months before Screening or is planning to donate blood
             during the study (due to HbA1c reading at screening)

         15. Other medical conditions that may diminish life expectancy to &lt;2 years, including
             known cancers

         16. Have been diagnosed with metastatic carcinomas in the last 5 years

         17. Has known allergies or hypersensitivity to metformin, sildenafil or leucine

         18. Have suffered myocardial infarction, stroke, arrhythmia in the last 6 months

         19. Resting hypotension (BP &lt;90/50 mmHg) or severe hypertension (BP &gt;170/110 mmHg) If both
             or one of the parameters for diastolic or systolic BP is meet

         20. Cardiac failure or coronary artery disease causing unstable angina

         21. History or evidence at screening of left ventricular outflow obstruction (e.g., aortic
             stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired
             autonomic control of blood pressure

         22. At risk for priapism due to anatomical deformation of the penis (e.g., angulation,
             cavernosal fibrosis, Peyronie's disease) or other conditions that predispose to
             priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia)

         23. Clinical evidence of hepatic impairment and/or ALT/AST &gt;5X ULN

         24. Is an immediate family member (spouse, parent, child, or sibling; biological or
             legally adopted) of personnel directly affiliated with the study at the clinical study
             site, or NuSirt Biopharma.

         25. Is employed by NuSirt Biopharma (defined as an employee, temporary contract worker, or
             designee responsible for the conduct of the study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Maximum of 70% female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael B Zemel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NuSirt Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMR</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACR</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMR</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACR</name>
      <address>
        <city>Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <results_first_submitted>October 29, 2018</results_first_submitted>
  <results_first_submitted_qc>October 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2018</results_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03364335/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03364335/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects meeting all inclusion criteria and no exclusion criteria were randomized to one of five treatment arms in the ratio of 1:1:1:1:1(A:B:C:D:E). The randomization was stratified by a maximum of 70% female with a BMI range between 30 kg/m2 and 45 kg/m2</recruitment_details>
      <pre_assignment_details>The discrepancy in the number of enrolled subjects and the actual number that started the study is because some of the enrolled subjects did not start the study for the following reasons: they moved, were not compliant with investigator request or were sent on active military duty.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: Placebo</description>
        </group>
        <group group_id="P2">
          <title>Leu Sil 1.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
        </group>
        <group group_id="P3">
          <title>Leu Sil 4.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
        </group>
        <group group_id="P4">
          <title>Leu Met Sil 1.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
        </group>
        <group group_id="P5">
          <title>Leu Met Sil 4.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who met the inclusion criteria, with BMI between 30kg/m2 and 45kg/m2.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Leu Sil 1.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
        </group>
        <group group_id="B3">
          <title>Leu Sil 4.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
        </group>
        <group group_id="B4">
          <title>Leu Met Sil 1.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
        </group>
        <group group_id="B5">
          <title>Leu Met Sil 4.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="53"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="258"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="258"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.29" spread="11.30"/>
                    <measurement group_id="B2" value="40.94" spread="11.14"/>
                    <measurement group_id="B3" value="39.55" spread="11.14"/>
                    <measurement group_id="B4" value="41.36" spread="12.66"/>
                    <measurement group_id="B5" value="42.89" spread="10.70"/>
                    <measurement group_id="B6" value="41.20" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.67" spread="13.856"/>
                    <measurement group_id="B2" value="105.05" spread="15.568"/>
                    <measurement group_id="B3" value="107.16" spread="17.962"/>
                    <measurement group_id="B4" value="100.18" spread="16.991"/>
                    <measurement group_id="B5" value="104.50" spread="17.405"/>
                    <measurement group_id="B6" value="103.74" spread="16.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.773" spread="3.31"/>
                    <measurement group_id="B2" value="37.179" spread="4.28"/>
                    <measurement group_id="B3" value="37.9" spread="4.20"/>
                    <measurement group_id="B4" value="36.425" spread="4.13"/>
                    <measurement group_id="B5" value="37.152" spread="4.23"/>
                    <measurement group_id="B6" value="36.89" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110.40" spread="10.998"/>
                    <measurement group_id="B2" value="112.91" spread="11.466"/>
                    <measurement group_id="B3" value="116.02" spread="12.411"/>
                    <measurement group_id="B4" value="111.17" spread="13.291"/>
                    <measurement group_id="B5" value="112.93" spread="13.311"/>
                    <measurement group_id="B6" value="112.71" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Body Weight Change</title>
        <description>The percentage body weight change from baseline to Day 168 was evaluated.</description>
        <time_frame>Baseline to Day 168</time_frame>
        <population>ANCOVA Analysis for Primary Endpoint – Percent Change in Body Weight from Baseline to Day 168 in per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Body Weight Change</title>
          <description>The percentage body weight change from baseline to Day 168 was evaluated.</description>
          <population>ANCOVA Analysis for Primary Endpoint – Percent Change in Body Weight from Baseline to Day 168 in per protocol population.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.121" spread="3.6241"/>
                    <measurement group_id="O2" value="0.674" spread="3.2286"/>
                    <measurement group_id="O3" value="-0.489" spread="3.9041"/>
                    <measurement group_id="O4" value="-0.929" spread="4.5533"/>
                    <measurement group_id="O5" value="-0.552" spread="2.5924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline body weight as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.5461</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline body weight as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0364</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline body weight as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0156</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline body weight as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0349</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Absolute Body Weight</title>
        <description>The change in absolute body weight from baseline to day 168 was evaluated.</description>
        <time_frame>Baseline to Day 168</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in Absolute Body Weight from Baseline to day 168 (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute Body Weight</title>
          <description>The change in absolute body weight from baseline to day 168 was evaluated.</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in Absolute Body Weight from Baseline to day 168 (Per-Protocol Population).</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.126" spread="3.5903"/>
                    <measurement group_id="O2" value="0.678" spread="3.2502"/>
                    <measurement group_id="O3" value="-0.460" spread="4.0352"/>
                    <measurement group_id="O4" value="-0.870" spread="4.5445"/>
                    <measurement group_id="O5" value="-0.461" spread="2.7583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline body weight as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.5348</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline body weight as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0379</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline body weight as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0215</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline body weight as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0464</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Patients With ≥5% Body Weight Loss</title>
        <description>The number of patients with ≥5% body weight loss in each group was assessed from baseline to day 168.</description>
        <time_frame>Baseline to Day 168</time_frame>
        <population>Analysis for Secondary Endpoint - Percentage of Subjects with ≥5% Relative Percentage Reduction from Baseline to day 168 in Body Weight by Treatment (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Patients With ≥5% Body Weight Loss</title>
          <description>The number of patients with ≥5% body weight loss in each group was assessed from baseline to day 168.</description>
          <population>Analysis for Secondary Endpoint - Percentage of Subjects with ≥5% Relative Percentage Reduction from Baseline to day 168 in Body Weight by Treatment (Per-Protocol Population).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Pearson’s Chi Square Test is used. Fisher exact test is used when any expected cell count is less than 5. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Pearson’s Chi Square Test is used. Fisher exact test is used when any expected cell count is less than 5. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.2646</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Pearson’s Chi Square Test is used. Fisher exact test is used when any expected cell count is less than 5. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0749</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Pearson’s Chi Square Test is used. Fisher exact test is used when any expected cell count is less than 5. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.6758</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <description>The change in waist circumference by using a tape measure across the mid-section was evaluated in subjects from baseline to day 168.</description>
        <time_frame>Baseline to Day 168</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in Waist Circumference from Baseline (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <description>The change in waist circumference by using a tape measure across the mid-section was evaluated in subjects from baseline to day 168.</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in Waist Circumference from Baseline (Per-Protocol Population).</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.043" spread="5.5591"/>
                    <measurement group_id="O2" value="0.028" spread="5.5152"/>
                    <measurement group_id="O3" value="-1.060" spread="5.5564"/>
                    <measurement group_id="O4" value="-1.841" spread="4.7654"/>
                    <measurement group_id="O5" value="0.637" spread="5.7908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline waist circumference as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.9656</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline waist circumference as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.4254</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline waist circumference as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.1276</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline waist circumference as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.5937</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol</title>
        <description>Changes in total cholesterol was examined by standard blood chemistry.</description>
        <time_frame>Baseline to Day 168</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol</title>
          <description>Changes in total cholesterol was examined by standard blood chemistry.</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="20.33"/>
                    <measurement group_id="O2" value="0.2" spread="20.96"/>
                    <measurement group_id="O3" value="1.9" spread="20.01"/>
                    <measurement group_id="O4" value="-0.7" spread="16.74"/>
                    <measurement group_id="O5" value="-6.6" spread="23.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.6010</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.6513</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.4354</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0310</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL Cholesterol</title>
        <description>Changes were measured in HDL cholesterol from Baseline to day 168 by standard blood chemistry.</description>
        <time_frame>Baseline, Day 168</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL Cholesterol</title>
          <description>Changes were measured in HDL cholesterol from Baseline to day 168 by standard blood chemistry.</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="7.43"/>
                    <measurement group_id="O2" value="0.6" spread="7.59"/>
                    <measurement group_id="O3" value="2.4" spread="6.40"/>
                    <measurement group_id="O4" value="1.8" spread="8.21"/>
                    <measurement group_id="O5" value="1.6" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.4644</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.8573</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.8167</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.9223</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL Cholesterol</title>
        <description>Changes in LDL Cholesterol was measured by standard blood chemistry from baseline to day 168.</description>
        <time_frame>Baseline, 168 days</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol</title>
          <description>Changes in LDL Cholesterol was measured by standard blood chemistry from baseline to day 168.</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="15.40"/>
                    <measurement group_id="O2" value="-6.6" spread="16.86"/>
                    <measurement group_id="O3" value="-4.2" spread="15.81"/>
                    <measurement group_id="O4" value="-5.5" spread="11.77"/>
                    <measurement group_id="O5" value="-11.6" spread="19.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.6574</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.8971</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.6317</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0341</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides</title>
        <description>The change in triglycerides was evaluated by standard blood chemistry in subjects from Baseline to Day 168.</description>
        <time_frame>Baseline, Day 168</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <description>The change in triglycerides was evaluated by standard blood chemistry in subjects from Baseline to Day 168.</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="45.43"/>
                    <measurement group_id="O2" value="9.7" spread="56.42"/>
                    <measurement group_id="O3" value="1.9" spread="51.93"/>
                    <measurement group_id="O4" value="-4.4" spread="47.02"/>
                    <measurement group_id="O5" value="3.5" spread="52.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.3720</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.2302</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.1377</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline fasting plasma lipid as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.4295</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Glucose</title>
        <description>Change in plasma glucose was examined through standard fasting blood chemistry.</description>
        <time_frame>Baseline to Day 168</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Glucose</title>
          <description>Change in plasma glucose was examined through standard fasting blood chemistry.</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in Fasting Plasma Lipids from Baseline to day 168 (Per-Protocol Population).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="7.98"/>
                    <measurement group_id="O2" value="-1.6" spread="9.35"/>
                    <measurement group_id="O3" value="0.3" spread="9.59"/>
                    <measurement group_id="O4" value="1.1" spread="12.43"/>
                    <measurement group_id="O5" value="-1.7" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline Fasting Plasma Glucose as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.6726</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline Fasting Plasma Glucose as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.7934</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline Fasting Plasma Glucose as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.5485</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline Fasting Plasma Glucose as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.3676</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin A1c (HbA1c)</title>
        <description>Change in Hemoglobin A1c was assessed in the subjects from baseline to day 168.</description>
        <time_frame>Baseline, Day 168</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in HbA1c from Baseline to day 168 (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c (HbA1c)</title>
          <description>Change in Hemoglobin A1c was assessed in the subjects from baseline to day 168.</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in HbA1c from Baseline to day 168 (Per-Protocol Population).</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.164"/>
                    <measurement group_id="O2" value="0.09" spread="0.167"/>
                    <measurement group_id="O3" value="0.11" spread="0.165"/>
                    <measurement group_id="O4" value="0.07" spread="0.198"/>
                    <measurement group_id="O5" value="0.09" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline HbA1c as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.1653</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline HbA1c as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.1970</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline HbA1c as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0608</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline HbA1c as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.1583</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure</title>
        <description>Diastolic blood pressure was measured by standard blood pressure monitor.</description>
        <time_frame>Baseline to Day 168</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in Blood Pressure from Baseline to day 168 (Per-Protocol Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure</title>
          <description>Diastolic blood pressure was measured by standard blood pressure monitor.</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in Blood Pressure from Baseline to day 168 (Per-Protocol Population)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="7.13"/>
                    <measurement group_id="O2" value="1.8" spread="9.57"/>
                    <measurement group_id="O3" value="-2.6" spread="8.10"/>
                    <measurement group_id="O4" value="1.1" spread="9.16"/>
                    <measurement group_id="O5" value="-3.3" spread="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline diastolic blood pressure as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0524</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline diastolic blood pressure as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.5221</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline diastolic blood pressure as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.3702</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline diastolic blood pressure as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.5426</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure</title>
        <description>Change in Systolic blood pressure was assessed in patients from baseline to Day 168</description>
        <time_frame>Baseline, Day 168</time_frame>
        <population>ANCOVA Analysis for Secondary Endpoint – Change in Blood Pressure from Baseline to day 168 (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <description>Change in Systolic blood pressure was assessed in patients from baseline to Day 168</description>
          <population>ANCOVA Analysis for Secondary Endpoint – Change in Blood Pressure from Baseline to day 168 (Per-Protocol Population).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="9.97"/>
                    <measurement group_id="O2" value="0.5" spread="12.21"/>
                    <measurement group_id="O3" value="-2.7" spread="9.12"/>
                    <measurement group_id="O4" value="0.6" spread="9.31"/>
                    <measurement group_id="O5" value="-3.5" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline systolic blood pressure as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.1843</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline systolic blood pressure as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.4411</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline systolic blood pressure as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.6991</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline systolic blood pressure as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.3721</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Markers</title>
        <description>hs-C-Reactive Protein (CRP) levels was examined by standard blood chemistry.</description>
        <time_frame>Baseline to Day 168</time_frame>
        <population>Descriptive Statistics for Secondary Endpoint – hs-C-Reactive Protein Change from Baseline to day 168 (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Leu Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Leu Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
          </group>
          <group group_id="O4">
            <title>Leu Met Sil 1.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
          <group group_id="O5">
            <title>Leu Met Sil 4.0mg</title>
            <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Markers</title>
          <description>hs-C-Reactive Protein (CRP) levels was examined by standard blood chemistry.</description>
          <population>Descriptive Statistics for Secondary Endpoint – hs-C-Reactive Protein Change from Baseline to day 168 (Per-Protocol Population).</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="2.401"/>
                    <measurement group_id="O2" value="0.12" spread="3.633"/>
                    <measurement group_id="O3" value="0.35" spread="3.385"/>
                    <measurement group_id="O4" value="0.56" spread="6.624"/>
                    <measurement group_id="O5" value="0.12" spread="3.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline hsCRP as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0318</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline hsCRP as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.3827</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline hsCRP as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.0050</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Analysis of covariance (ANCOVA) model: with treatment group and time as the main effects and baseline hsCRP as the covariate. Treatment A is used as the reference group.</non_inferiority_desc>
            <p_value>0.1045</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Treatment-Emergent Adverse Event (TEAE) is defined as an adverse event occuring on (or) after the first dose of randomized Study medication, (or) existing prior to the time of and worsening after the time of the first dose of randomized study medication. N:number of subjects in the Intent-to-Treat population; n:number of subjects in the category; %:percentage calculated using the N as the denominator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Leu Sil 1.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID</description>
        </group>
        <group group_id="E3">
          <title>Leu Sil 4.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID</description>
        </group>
        <group group_id="E4">
          <title>Leu Met Sil 1.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 1.0 mg: Sildenafil 1.0 mg BID
Metformin: Metformin 500 mg BID</description>
        </group>
        <group group_id="E5">
          <title>Leu Met Sil 4.0mg</title>
          <description>3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
Leucine: 1100 mg BID
Sildenafil Citrate 4.0 mg: Sildenafil 4.0 mg BID
Metformin: Metformin 500 mg BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Cannon</name_or_title>
      <organization>NuSirt Biopharma</organization>
      <phone>6156567898</phone>
      <email>BCannon@nusirt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

